Diabetes Therapeutics Market in India to 2018 – Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 10
2 Diabetes Therapeutics Market in India to 2018 – Overview 11
2.1 Diabetes Mellitus – A Global Overview 11
3 Diabetes Therapeutics Market in India – Introduction 12
3.1 Type 1 Diabetes Mellitus 12
3.1.1 People at Risk 12
3.1.2 Risk Factors for Type 1 Diabetes 12
3.1.3 Symptoms 12
3.2 Type 2 Diabetes Mellitus 13
3.2.1 People at Risk 13
3.2.2 Risk Factors for Type 2 Diabetes 13
3.2.3 Symptoms 13
3.3 Gestational Diabetes Mellitus 13
3.3.1 Risk Factors for Gestational Diabetes Mellitus 13
3.4 Diagnosis of Diabetes Mellitus 14
3.5 Diabetes Treatment Guidelines – India 15
3.5.1 Introduction 15
3.5.2 Prevention of Diabetes 15
3.5.3 Diabetes Treatment 15
3.6 Diabetes Mellitus Complications 16
4 Diabetes Therapeutics Market in India to 2018 – Major Drug Classes 17
4.1 Sulfonylureas 17
4.1.1 Introduction 17
4.1.2 Mechanism of Action 17
4.1.3 Major Drugs 18
4.2 Thiazolidinediones 18
4.2.1 Introduction 18
4.2.2 Mechanism of Action 18
4.2.3 Example 18
4.3 Biguanides 19
4.3.1 Introduction 19
4.3.2 Mechanism of Action 19
4.3.3 Drug Products 19
4.4 Meglitinides 20
4.4.1 Introduction 20
4.4.2 Mechanism of Action 20
4.4.3 Major Drugs 20
4.5 Alpha-Glucosidase Inhibitors 21
4.5.1 Introduction 21
4.5.2 Mechanism of Action 21
4.5.3 Major Drugs 21
4.6 Glucagon-Like Peptide Analogs and Agonists 22
4.6.1 Description 22
4.6.2 Mechanism of Action 22
4.6.3 Major Drugs 22
4.7 Dipeptidyl Peptidase-4 Inhibitors 22
4.7.1 Description 22
4.7.2 Mechanism of Action 22
4.7.3 Major Drugs 23
4.8 Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors 23
4.9 Insulin Preparations 23
4.9.1 Introduction 23
4.9.2 Types of Insulin 23
5 Diabetes Therapeutics Market in India to 2018 – Epidemiology 25
5.1 Introduction 25
5.2 Diabetes Population in India 27
5.3 Diagnosed Population 29
5.4 Treated Population 29
6 Diabetes Therapeutics Market in India to 2018 – Revenue Forecasts 30
6.1 Introduction 30
6.1.1 Oral Anti-Diabetics Market 31
6.1.2 Insulin Market 31
6.2 Annual Cost of Therapy 32
7 Diabetes Therapeutics Market in India to 2018 – Economic Burden of Diabetes in India 33
7.1 Economic Burden of Diabetes in India 33
7.1.1 Introduction 33
7.1.2 Healthcare Expenditure on Diabetes in India 33
7.2 Collaborative Efforts Necessary to Address the Rising Burden of Diabetes 34
8 Diabetes Therapeutics Market in India to 2018 – Drivers and Barriers 35
8.1 Market Drivers 35
8.1.1 Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India 35
8.1.2 Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy 35
8.1.3 Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies 36
8.2 Market Barriers 36
8.2.1 Low Diagnosis and Prescription Rate 36
8.2.2 Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure 36
8.2.3 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes 37
9 Diabetes Therapeutics Market in India to 2018 – Unmet Needs 38
9.1 Introduction 38
9.2 High Cost of Therapy and Drug Safety Issues Affect Patient Compliance 38
9.3 Unmet Need Creates Opportunities for Pharmaceutical Companies 38
10 Diabetes Therapeutics Market in India to 2018 – Product Pipeline Analysis 39
10.1 Profiles of Promising Molecules in R&D Development 40
10.1.1 IN-105 (Oral Insulin) 40
10.1.2 NN9068/IDegLira/degludec +/- liraglutide 40
10.1.3 Dapagliflozin 41
10.1.4 Canagliflozin/TA-7284 42
10.1.5 Lixisenatide 42
10.1.6 Alogliptin 42
11 Diabetes Therapeutics Market in India to 2018 – Case Studies 43
11.1 Avandia Fallout Impact 43
11.1.1 Introduction 43
11.1.2 Cardiovascular Safety Issues 43
11.1.3 Impact on GlaxoSmithKline 43
11.1.4 Impact on Drug Approvals 43
11.2 Januvia from Merck an Example that Patented Products can succeed in India 44
11.2.1 Introduction 44
11.2.2 Improved Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption 44
11.2.3 Januvia and Janumet a New Growth Engine for Merck 44
11.2.4 Robust Approach Needed to Market a New Drug Product in India 44
11.2.5 Excellent Commercialization Strategy 45
11.2.6 Conclusion 45
12 Diabetes Therapeutics Market in India to 2018 – Major Trends and Issues 46
12.1 Biguanides Class is dominated by Generics 46
12.2 Evolving Oral Hypoglycemic Agents Resulting in Smaller Market Share Sulfonylureas 46
12.3 Increasing Competition in Dipeptidyl Peptidase-4 Inhibitor Class 46
12.3.1 DPP-4 Inhibitors Likely to Face Potential Competition from GLP-1 Agonists 46
12.4 Thiazolidinedione Class to Face Impact of Avandia Fallout 47
12.5 GLP-1 Agonists Must Demonstrate Better Safety and Efficacy Profiles to Compete with other Oral Hypoglycemic Class 47
12.6 Fierce Competition in the Insulin Market is Likely to Increase 48
12.7 Is Oral Insulin the Next Big Thing in the Insulin Market? 48
12.7.1 Introduction 48
12.7.2 Oral Insulin Not for All 48
12.7.3 Challenges to Overcome 48
12.7.4 Would it lead to Market Cannibalization? 49
12.8 India Diabetes Market: Setting up for the Biosimilars? 49
12.8.1 Introduction 49
12.8.2 Insulin Biosimilar Market 49
12.8.3 Sanofi’s Lantus a Lucrative Target 49
12.8.4 Need for Dose Adjustments would Discourage Uptake of Biosimilars 50
12.8.5 Price Discounts Alone would be Insufficient 50
12.8.6 Strong Brand Promotion would be Necessary for Insulin Biosimilars 50
12.8.7 Collaborations and Licensing Agreements are Key 50
12.8.8 Conclusion 51
12.9 Sodium Glucose Co-Transporter2 Inhibitors: A New Class to Hit the Market? 51
12.10 Glucokinase Activators 51
12.11 Stem Cell Therapies: The Next Prospective Therapy for Diabetes? 52
12.11.1 Introduction 52
12.11.2 What are Stem Cells? 52
12.11.3 Stem Cell Therapies and Diabetes 52
12.11.4 Conclusion 52
12.12 Price Discounts a Decisive Factor in the Increasingly Competitive Anti-Diabetes Market 53
12.13 Favorable Government Polices to Promote Generics 53
12.14 Strategic Consolidation to Increase Growth Prospects 54
12.14.1 Introduction 54
12.14.2 Shift of Focus towards Rural and Class II-IV Towns 54
13 Diabetes Therapeutics Market in India to 2018 – Competitive Landscape 55
13.1 Novartis India Limited (Novartis India) 55
13.2 Novo Nordisk India Private Limited (Novo) 56
13.3 Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly) 57
13.4 Merck Sharp Dohme India 57
13.5 Abbott India Limited (Abbott India) 58
13.6 Sun Pharmaceutical Industries Limited (Sun Pharma) 59
13.7 USV Limited 60
13.8 Wockhardt Limited (Wockhardt) 61
13.9 Sanofi India Limited 62
13.10 Biocon Limited (Biocon) 63
14 Diabetes Therapeutics Market in India to 2018 – Strategic Consolidations 64
14.1 Introduction 64
14.2 Diabetology Entered into Licensing Agreement with USV for Capsulin on July 31, 2012 64
14.3 Merck Sharp & Dohme Entered into Co-Marketing Agreement with Sun Pharma on April 25, 2011 64
14.4 Eli Lilly and Company (India) Entered into Co-Promotion Agreement with Lupin on July 29, 2011 65
14.5 Sheffield Bio-Science Entered into Collaboration with Wockhardt on February 21, 2011 65
14.6 Eli Lilly Entered into Co-Promotion Agreement with Boehringer Ingelheim for Humalog and Linagliptin on October 3, 2011 65
14.7 Novartis India Entered into Co-Marketing Agreement with USV on December 31, 2008 65
14.8 Pfizer-Biocon Deal Called Off in March 2012 66
14.8.1 Impact Analysis 66
15 Diabetes Therapeutics Market in India to 2018 – Appendix 67
15.1 Market Definitions 67
15.2 Abbreviations 67
15.3 Bibliography 68
15.4 Research Methodology 69
15.4.1 Coverage 69
15.4.2 Secondary Research 70
15.4.3 Primary Research 70
15.5 Therapeutic Landscape 71
15.5.1 Market 73
15.6 Geographical Landscape 74
15.7 Pipeline Analysis 74
15.8 Competitive Landscape 74
15.8.1 Expert Panel Validation 74
15.9 Contact Us 74
15.10 Disclaimer 74